利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性观察 |
| |
引用本文: | 张萍,潘天荣,钟兴,杜益君. 利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性观察[J]. 中华糖尿病杂志, 2014, 22(11): 974-977 |
| |
作者姓名: | 张萍 潘天荣 钟兴 杜益君 |
| |
作者单位: | 安徽医科大学第二附属医院内分泌科,合肥,230601 |
| |
基金项目: | 安徽省高等学校省级自然科学基金,安徽医科大学校级科学基金 |
| |
摘 要: | 目的 探讨利拉鲁肽联合胰岛素治疗新诊断肥胖T2DM的临床疗效及安全性. 方法 筛选新诊断肥胖T2DM患者76例,按数字随机表法分为观察组和对照组,每组各38例.对照组予胰岛素联合二甲双胍,观察组在此基础上加用利拉鲁肽.治疗16周,比较两组治疗的临床疗效及不良反应.结果 与治疗前相比,两组糖基化血红蛋白[对照组:(10.94±1.55)% vs (6.90±0.75)%;观察组:(11.41±1.43)%vs(5.86±0.76)%]、稳态模型胰岛素抵抗指数(HOMA-IR)下降[对照组:(3.40±0.63)vs(2.00±0.35);观察组:(3.38±0.66)vs(1.60±0.54)](P均<0.05),而稳态模型胰岛β细胞功能指数(HOMA-β)升高[(对照组:(13.34±4.07)vs(33.56±7.06);观察组:(12.53±3.25) vs (49.88±10.58)](P<0.05);观察组BMI降低[(28.89±1.19) vs(26.58±0.93) kg/m2] (P<0.01).与对照组相比,观察组治疗后HbA1 c下降[(6.90土0.75)%vs(5.86±0.76)%]、HOMA-IR [(2.00±0.35)vs (1.60±0.54)] HOMA-β升高[(33.56±7.06)vs(49.88±10.58)](P<0.05);观察组低血糖发生率升高[(72.1%vs81.6%)](P<0.05).两组均无严重低血糖事件发生. 结论 利拉鲁肽联合胰岛素治疗新诊断肥胖T2DM可明显降低血糖和体重,改善胰岛β细胞功能,且无严重不良反应发生.
|
关 键 词: | 糖尿病,2型 新诊断 肥胖 利拉鲁肽 胰岛素 |
Efficacy and safety observation of liraglutide and insulin as combination therapy in the treatment of newly diagnosed type 2 diabetes with obesity |
| |
Affiliation: | ZHANG Ping, PAN Tian-rong , ZHONG Xing , et al. (Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, He f ei 230601 ,China) |
| |
Abstract: | Objective To assess the efficacy and safety of liraglutide and insulin as combination therapy in the treatment of newly diagnosed type 2 diabetes with obesity.Methods A 16-week,randomized,parallel-group study was carried out.A total of 76 patients completed the trial who had been randomly assigned to either the liraglutide-added group (the observer group) or the group of insulin combined with metformin only(the control group).Efficacy and adverse reactions were evaluated.Results After intervention,glycated hemoglobin A1c (HbA1 c) [the control group (10.94 ± 1.55) % vs (6.90±0.75) %,the observer group (11.41±1.43)% vs (5.86±0.76)%] and insulin resistance index (HOMAIR)[the control group (3.40±0.63) vs (2.00±0.35),the observer group (3.38±0.66) vs (1.60±0.54)] decreased significantly,while homeostatic model assessment of the insulin secretion index (HOMA-β)[the control group (13.34±4.07) vs (33.56±7.06),the obser-ver group (12.53±3.25) vs (49.88±10.58)](P〈0.05) increased significantly in all two groups(all P〈0.05);The body mass index (BMI) decreased significantly in observer group (28.89 ± 1.19) vs (26.58 ± 0.93) kg/m2 ; The HbA1 c (6.90±0.75) % vs (5.86 ± 0.76) % and the HOMAIR (2.00 ± 0.35) vs (1.60 ± 0.54) decreased furtherin observer group when compared with the control group,while the HOMA-β was significant higher (33.56±7.06) vs (49.88±10.58) (P〈0.05).The incidence of hypoglycemia was higher in the observer group when compared with the control group (81.6 % vs 72.1 %)(P〈0.05).Serious hypoglycemia was not happented in two group.Conclusion The treatment of Adding liraglutide to insulin in newly diagnosed type 2 diabetes with obesity can induce a significant reduction in blood glucose and body weight; Improve function of β-cell.Serious adverse reactions were not happented. |
| |
Keywords: | Diabetes mellitus,type 2 Newly diagnosed Obesity Liraglutide Insulin |
本文献已被 维普 等数据库收录! |
|